RB1 and glioblastoma: Some GBM tumors treated with temozolamide exhibited a mutator phenotype, resulting from mutations in MMR genes, and were found to harbor driver mutations in RB1 (encoding retinoblastoma 1), PIK3CA and PTEN that bore the signature of temozolamide-induced mutagenesis [21,45].